Pembro/Pemetrexed-Platinum: How Does It Affect Patient QOL?

In patients with previously untreated, metastatic, non-squamous non-small cell lung cancer (NSCLC), pembrolizumab plus pemetrexed-platinum has proven to be an effective treatment compared with pemetrexed-platinum alone in increasing the proportion of patients who experience a complete or partial response, as shown in the KEYNOTE-189 study. Based on the results of this study, the FDA recently approved a new indication for pemetrexed in this combination for the first-line treatment ...
Continue reading

Atezolizumab Plus nab-Paclitaxel and Carboplatin FDA Approved for Metastatic NSCLC

Atezolizumab (Tecentriq®, Genentech Inc.) in combination with nab-paclitaxel and carboplatin is now FDA approved as first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. Atezolizumab, previously approved to treat extensive-stage small cell lung cancer, metastatic urothelial carcinoma, and metastatic triple-negative breast cancer, works as a monoclonal antibody and stimulates the immune system by block...
Continue reading

Osimertinib for EGFR-Mutated Advanced NSCLC: An Interview with Suresh S. Ramalingam, MD

The treatment of advanced-stage non-small cell lung cancer (NSCLC) has improved steadily in the past few years, and individualized therapy for patients with mutations in the epidermal growth factor receptor (EGFR) is applied in routine clinical practice. While EGFR-mutated NSCLC is effectively treated with tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib, there is a need to develop more effective treatments to improve outcomes in these patients. In a study now published in The Ne...
Continue reading

Finding Solutions in Advanced NSCLC Without Driver Mutations: Jamie E. Chaft, MD

​Many patients with non-small cell lung cancer (NSCLC) present with advanced disease, which is highly resistant to chemotherapy. Recently, the use of tumor histology and relevant molecular biomarkers in determining optimal treatment strategies has improved outcomes for some patients, yet a number of targeted therapies are not applicable to patients without driver mutations. In this interview with i3 Health, Jamie E. Chaft, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center and an...
Continue reading

Pembrolizumab After Locally Ablative Therapy in NSCLC: Joshua Bauml, MD

Locally ablative therapy, which consists of surgery, radiation, and other definitive treatments at all sites of metastasis, has shown efficacy in oligometastatic non-small cell lung cancer (NSCLC). Given that immunotherapy has also shown efficacy in NSCLC, Joshua Bauml, MD, and colleagues at the University of Pennsylvania's Perelman School of Medicine investigated the combination of locally ablative therapy with pembrolizumab (Keytruda®, Merck). The investigators found that adding pembrolizumab ...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.